Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

Strategies to enhance virtual care through quality assurance frameworks, technological innovation, and provider support were ...

Anna Mueller, MD, Mount Sinai, presented the findings at the American College of Cardiology 2025 Annual Scientific Session ...

Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to ...

Panelists explored responsible, patient-centered use of artificial intelligence (AI) in cardiovascular care at the American ...

The long-term impact of disruptions in oncology care during the COVID-19 pandemic will become more apparent in the coming years, according to Dan Nardi, MS, of Reimagine Care.

To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not ...

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing ...

Susan Cantrell, CEO of the Academy of Managed Care Pharmacy, breaks down some of the key conference topics that will be ...